Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephalexin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.98 |
| ▸ | MAPT | P10636 | 8/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.96 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.96 |
| ▸ | HPGD | P15428 | 3/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.96 |
| ▸ | BLM | P54132 | 2/20 | 0.96 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.96 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.96 |
| ▸ | HTR2B | P41595 | 1/20 | 0.96 |
| ▸ | MEN1 | O00255 | 5/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | ESR1 | P03372 | 1/20 | 0.81 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.81 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephalexin Anhydrous SCHEMBL27742537 | 1.00 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL4928321 | 1.00 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL4928314 | 1.00 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL2353787 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL5049268 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL41911 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL40988 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL2353794 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL21962879 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL3002253 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 551 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104825397-A | Controlled release delivery device containing organosol coating | ISA ODIDI | 2015-08-12 | — | — | CN | claimed |
| EP-2432535-A2 | DRY POWDER INHALERS | 3M Innovative Properties Company (US) | 2012-03-28 | — | — | EP | claimed |
| WO-2010135340-A2 | DRY POWDER INHALERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-11-25 | — | — | WO | claimed |
| EP-2007360-A1 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT | Odidi, Isa (CA) | 2008-12-31 | — | — | EP | claimed |
| WO-2007112581-A1 | CONTROLLED RELEASE DELIVERY DEVICE COMPRISING AN ORGANOSOL COAT | ODIDI ISA (CA) | 2007-10-11 | — | — | WO | claimed |
| EP-0143658-B1 | IMPROVEMENTS IN OR RELATING TO CEPHALOSPORIN DERIVATIVES | ELI LILLY AND COMPANY (US) | 1989-03-22 | — | — | EP | claimed |
| US-4600773-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1986-07-15 | — | — | US | claimed |
| EP-0143658-A2 | Improvements in or relating to cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1985-06-05 | — | — | EP | claimed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250152703-A1 | COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-15 | — | — | US | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| US-4775751-A | Process for cephalexin hydrochloride alcoholates | ELI LILLY & COMPANY (US) | 1988-10-04 | — | — | US | disclosed |
| US-4600773-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| US-4600773-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| US-4600773-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
| EP-0143658-A2 | Improvements in or relating to cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1985-06-05 | — | — | EP | disclosed |
| EP-0143658-A2 | Improvements in or relating to cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | HSD17B10 2103/4885MAPT 257/4885ALDH1A1 2656/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | HSD17B10 3050/4885MAPT 497/4885ALDH1A1 4424/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | HSD17B10 2677/4885MAPT 153/4885ALDH1A1 4450/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | HSD17B10 942/4885MAPT 4544/4885ALDH1A1 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.